http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003225030-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c094ddce99a7e57c7498562a504d7817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c701aeaf985bc9ee2ed856f87567a19f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-525 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-714 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-525 |
| filingDate | 2002-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fcd671db9923b387d1a59315036b9db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8e518ae7e2dbadb31e1c4ff337343ad |
| publicationDate | 2003-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003225030-A1 |
| titleOfInvention | Non-liquid vitamin compositions |
| abstract | A method for orally administering vitamin preparations is described which combine vitamin B 12 (B 12 , cobalamin) and folic acid (folate), with and without pyridoxine (B 6 ), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of B 12 and/or folic acid deficiencies. Further, it is likely that a B 6 deficiency may be present with a B 12 or folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. The method of the present invention eliminates the costly and time consuming steps of distinguishing between vitamin deficiencies once a deficiency is found by measurement of serum metabolite levels. The present invention is of particular benefit to the populations at risk for elevated serum metabolite levels, such as the people over the age of 65, and populations that have or are at risk for neuropsychiatric, vascular, renal and hematologic diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008139498-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7053065-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7994142-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8697669-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006092294-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009253649-A9 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7772209-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006074918-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010210583-A1 |
| priorityDate | 1992-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.